sulforaphane has been researched along with Diabetes Mellitus, Type 1 in 4 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results suggest that type 1 diabetes significantly induced testicular apoptosis and damage along with increasing oxidative stress and cell death and suppressing Nrf2 expression and function." | 1.40 | Protection by sulforaphane from type 1 diabetes-induced testicular apoptosis is associated with the up-regulation of Nrf2 expression and function. ( Bai, Y; Cai, L; Jiang, X; Xin, Y; Zhang, Z, 2014) |
| "Sulforaphane (SFN) is a compound which is found in cruciferous vegetables and that acts as both a potent antioxidant and regulator of gene expression." | 1.38 | Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats. ( de Assis, AM; de Souza, CG; Perry, ML; Rech, A; Sattler, JA; Souza, DO, 2012) |
| "Sulforaphane (SFN) is an indirect antioxidant that protects animal tissues from chemical or biological insults by stimulating the expression of several NF-E2-related factor-2 (Nrf2)-regulated phase 2 enzymes." | 1.35 | Sulforaphane protects against cytokine- and streptozotocin-induced beta-cell damage by suppressing the NF-kappaB pathway. ( Kim, EK; Kim, HJ; Kwon, KB; Moon, WS; Park, BH; Park, JW; Park, R; So, HS; Song, MY, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, J | 1 |
| Wang, S | 1 |
| Wang, W | 1 |
| Chen, J | 1 |
| Zhang, Z | 2 |
| Zheng, Q | 1 |
| Liu, Q | 1 |
| Cai, L | 2 |
| Jiang, X | 1 |
| Bai, Y | 1 |
| Xin, Y | 1 |
| Song, MY | 1 |
| Kim, EK | 1 |
| Moon, WS | 1 |
| Park, JW | 1 |
| Kim, HJ | 1 |
| So, HS | 1 |
| Park, R | 1 |
| Kwon, KB | 1 |
| Park, BH | 1 |
| de Souza, CG | 1 |
| Sattler, JA | 1 |
| de Assis, AM | 1 |
| Rech, A | 1 |
| Perry, ML | 1 |
| Souza, DO | 1 |
4 other studies available for sulforaphane and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice.
Topics: Animals; Cardiotonic Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Ca | 2019 |
Protection by sulforaphane from type 1 diabetes-induced testicular apoptosis is associated with the up-regulation of Nrf2 expression and function.
Topics: Animals; Antioxidants; Apoptosis; Apoptosis Regulatory Proteins; Cell Proliferation; Cytoprotection; | 2014 |
Sulforaphane protects against cytokine- and streptozotocin-induced beta-cell damage by suppressing the NF-kappaB pathway.
Topics: Animals; Cell Death; Cell Line; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2009 |
Metabolic effects of sulforaphane oral treatment in streptozotocin-diabetic rats.
Topics: Animals; Antioxidants; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Dietary Supplements; Gluco | 2012 |